Anticancer drug nephrotoxicity is a common problem encountered by the nephrologist. The number of drugs causing acute and chronic kidney injury as well as electrolyte and acid-base disturbances has increased significantly over the past 10 to 20 years. Clinicians must be knowledgeable in the renal metabolism and excretion of these agents to assure efficacy and to avoid systemic toxicity, especially in patients with underlying kidney disease. Chemotherapeutic drugs induce acute kidney injury from a number of lesions including acute tubular injury, acute interstitial nephritis, and a variety of glomerular injuries. In addition to nephrotoxicity associated with conventional chemotherapy, the emergence of targeted therapies and novel immunotherapies has increased the occurrence of drug-induced acute and chronic kidney injury in cancer patients. This article will reflect some of the information on anticancer drug nephrotoxicity, which I presented at the New Horizons in Nephrology Updates in Onco-Nephrology Symposium in Philadelphia, Pennsylvania, USA.
EreminaVJeffersonJAKowalewskaJet al.VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med2008; 358(11): 1129–1136
9.
TeumaCPerier-MuzetMPelletierSet al.New insights into renal toxicity of the B-RAF inhibitor, vemurafenib, in patients with metastatic melanoma. Cancer Chemother Pharmacol2016; 78(2): 419–426
10.
PerazellaMAIzzedineHNew drug toxicities in the onco-nephrology world. Kidney Int2015; 87(5): 909–917
11.
IzzedineHEl-FekihRKPerazellaMAThe renal effects of ALK inhibitors. Invest New Drugs2016; 34(5): 643–649
12.
CortazarFBMarroneKATroxellMLet al.Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. Kidney Int2016; 90(3): 638–647
13.
ShiraliACPerazellaMAGettingerSAssociation of acute interstitial nephritis with Programmed Cell Death 1 inhibitor therapy in lung cancer patients. Am J Kidney Dis2016; 68(2): 287–291
14.
IzzedineHPerazellaMAThrombotic microangiopathy, cancer, and cancer drugs. Am J Kidney Dis2015; 66(5): 857–868
GlezermanIKrisMGMillerVSeshanSFlombaumCDGemcitabine nephrotoxicity and hemolytic uremic syndrome: report of 29 cases from a single institution. Clin Nephrol2009; 71(2): 130–139
19.
KondoHMoriAAnti-tumor activity of pamidronate in human multiple myeloma. Leuk Lymphoma2002; 43(4): 919–921
PerazellaMACrystal-induced acute renal failure. Am J Med1999; 106(4): 459–465
24.
PinheiroFVPimentelVCDe BonaKSet al.Decrease of adenosine deaminase activity and increase of the lipid peroxidation after acute methotrexate treatment in young rats: protective effects of grape seed extract. Cell Biochem Funct2010; 28(1): 89–94
25.
de MiguelDGarcía-SuárezJMartínYGil-FernándezJJBurgaletaCSevere acute renal failure following high-dose methotrexate therapy in adults with haematological malignancies: a significant number result from unrecognized co-administration of several drugs. Nephrol Dial Transplant2008; 23(12): 3762–3766
26.
CeltikciBLeclercDLawranceAKet al.Altered expression of methylenetetrahydrofolate reductase modifies response to methotrexate in mice. Pharmacogenet Genomics2008; 18(7): 577–589
27.
WallSMJohansenMJMolonyDADuBoseTDJrJaffeNMaddenTEffective clearance of methotrexate using high-flux hemodialysis membranes. Am J Kidney Dis1996; 28(6): 846–854
28.
WidemannBCSchwartzSJayaprakashNet al.Efficacy of glucarpidase (carboxypeptidase g2) in patients with acute kidney injury after high-dose methotrexate therapy. Pharmacotherapy2014; 34(5): 427–439
29.
GurevichFPerazellaMARenal effects of anti-angiogenesis therapy: update for the internist. Am J Med2009; 122(4): 322–328
30.
IzzedineHMangierMOryVet al.Expression patterns of RelA and c-mip are associated with different glomerular diseases following anti-VEGF therapy. Kidney Int2014; 85(2): 457–470
31.
ZhuXWuSDahutWLParikhCRRisks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis2007; 49(2): 186–193
32.
MuallemSMoeOWWhen EGF is offside, magnesium is wasted. J Clin Invest2007; 117(8): 2086–2089
MarkowitzGSBombackASPerazellaMADrug-induced glomerular disease: direct cellular injury. Clin J Am Soc Nephrol2015; 10(7): 1291–1299
40.
MarkowitzGSNasrSHStokesMBDAgatiVDTreatment with IFN-alpha, -beta, or -gamma is associated with collapsing focal segmental glomerulosclerosis. Clin J Am Soc Nephrol2010; 5(4): 607–615
PortaCMoroniMBobbio-PallaviciniETinelliCRegazzi-BonoraMNitrate plasma level as a marker of nitric oxide production after subcutaneous interleukin 2 immunotherapy. J Natl Cancer Inst1997; 89(20): 1545
43.
MemoliBDe NicolaLLibettaCet al.Interleukin-2-induced renal dysfunction in cancer patients is reversed by low-dose dopamine infusion. Am J Kidney Dis1995; 26(1): 27–33
44.
PostowMACallahanMKWolchokJDImmune Checkpoint Blockade in Cancer Therapy. J Clin Oncol2015; 33(17): 1974–1982
GillSMausMVPorterDLChimeric antigen receptor T cell therapy: 25 years in the making. Blood Rev2016; 30(3): 157–167
47.
FreyNVPorterDLCytokine release syndrome with novel therapeutics for acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program2016; 2016(1): 567–572
48.
FitzgeraldJCWeissSLMaudeSLet al.Cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia. Crit Care Med2017; 45(2): e124–e131
49.
LeeDWBarrettDMMackallCet al.The future is now: chimeric antigen receptors as new targeted therapies for childhood cancer. Clin Cancer Res2012; 18(10): 2780–2790
50.
MaudeSLFreyNShawPAet al.Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med2014; 371(16): 1507–1517
51.
BonifantCLJacksonHJBrentjensRJCurranKJToxicity and management in CAR T-cell therapy. Mol Ther Oncolytics2016316011
52.
BrudnoJNKochenderferJNToxicities of chimeric antigen receptor T cells: recognition and management. Blood2016; 127(26): 3321–3330
53.
GruppSAKalosMBarrettDet al.Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med2013; 368(16): 1509–1518
